Biological evaluation of medical devices — Part 3: Evaluation of genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity
Introduction: The basis for biological evaluation of medical devices is often empirical and driven by relevant concerns for human safety. The risk of serious and irreversible effects, such as cancer or second-generation abnormalities, is of particular public concern. It is inherent in the provision of safe medical devices that such risks be minimized to the greatest extent feasible. The assessment of mutagenic, carcinogenic, reproductive toxicity and developmental toxicity hazards is an essential component of the control of these risks. Not all test methods for the assessment of genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity are equally well developed, nor is their validity well established for the testing of medical devices. Significant issues with test sample size and preparation, scientific understanding of disease processes and test validation can be cited as limitations of available methods. Since the previous edition of this document, many genotoxicity test methods have been updated with revised OECD guidelines. However, these generally provide clearer recommendations but little alteration in test methods. Scientifically sound alternatives to the proposed testing can be acceptable insofar as they address relevant matters of safety assessment of the medical device. In the selection of tests needed to evaluate a particular medical device, a careful assessment of expected human uses and potential interactions with biological systems is important, particu
Scope: This document specifies strategies for risk estimation and evaluation of biological harms with respect to: — genotoxicity; — carcinogenicity; — reproductive toxicity; and — developmental toxicity. This document is applicable when the need to evaluate a medical device for potential genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity has been established. This document is not applicable to active pharmaceutical ingredients of device-drug combination products or biological components of device-biologic combination products which are covered by regulations. NOTE Guidance on selecting relevant biological effects for medical devices is covered in ISO 10993-1.